活检前MRI阴性后临床显著前列腺癌检出:双参数与多参数MRI的比较
该回顾性研究比较了活检前双参数MRI(bpMRI)与多参数MRI(mpMRI)阴性后临床显著前列腺癌(csPCa)的检出频率。bpMRI组232例,mpMRI组193例,PI-RADS 1或2类定义为阴性。阴性后行系统穿刺活检者中,csPCa检出率bpMRI组15.6%(15/96) vs mpMRI组13.6%(8/59),差异无统计学意义(p=.69)。PSAD在两队列中对csPCa的诊断效能相似。
要点
- 活检前bpMRI或mpMRI阴性后,系统穿刺活检的csPCa检出率无显著差异。
- PSAD是csPCa的独立预测因子(OR 3.09,p<.001),前列腺体积较小亦为独立预测因子(OR 0.27,p<.001)。
- PSAD阈值0.15 ng/mL²时,bpMRI队列NPV 90%、PPV 28%,mpMRI队列NPV 92%、PPV 44%。
核心结论
- 活检前bpMRI与mpMRI阴性后系统穿刺活检的csPCa检出频率无显著差异,PSAD在两队列中对csPCa的诊断效用相似。
研究设计与样本
- 回顾性研究,bpMRI组232例(平均年龄64.5岁,2017年8月至2020年3月),mpMRI组193例(平均年龄69.0岁,2018年1月至2018年12月);PI-RADS 1或2类定义为阴性;csPCa定义为Gleason评分≥3+4。
诊断标准与关键数值
- csPCa定义为Gleason评分3+4或更高;PSAD对csPCa的AUC在bpMRI队列为0.71(95%CI 0.56-0.87),在mpMRI队列为0.68(95%CI 0.42-0.93);PSAD阈值0.15 ng/mL²时,bpMRI队列NPV 90%、PPV 28%,mpMRI队列NPV 92%、PPV 44%。
临床应用与阅片要点
- 作者结论认为,bpMRI或mpMRI联合PSAD测量有助于避免阴性前列腺穿刺活检。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The frequency of clinically significant prostate cancer (csPCa) following negative biparametric MRI (bpMRI) and multiparametric MRI (mpMRI) has not been well investigated in direct comparative studies. OBJECTIVE. The purposes of this study were to compare the frequency of csPCa after negative prebiopsy bpMRI and mpMRI and to evaluate factors predictive of csPCa in the two cohorts. METHODS. This retrospective study included 232 men (mean age, 64.5 years) with negative bpMRI from August 2017 to March 2020 and 193 men (mean age, 69.0 years) with negative mpMRI from January 2018 to December 2018. PI-RADS category 1 or 2 was defined as negative. The study institution offered bpMRI as a low-cost self-pay option for patients without insurer coverage of prebiospy mpMRI. Patient characteristics and subsequent biopsy results were recorded. CsPCa was defined as Gleason score of 3 + 4 or greater. Multivariable regression analyses were performed to identify independent predictors of csPCa. The AUC of PSA density (PSAD) for csPCA was computed, and the diagnostic performance of PSAD was assessed at a clinically established threshold of 0.15 ng/mL2. RESULTS. Systematic biopsy was performed after negative bpMRI for 41.4% (96/232) of patients and after negative mpMRI for 30.5% (59/193) (p = .02). Among those undergoing biopsy, csPCa was present in 15.6% (15/96) in the bpMRI cohort versus 13.6% (8/59) in the mpMRI cohort (p = .69). The NPV for csPCa was 84% (81/96) for bpMRI and 86% (51/59) for mpMRI. In multivariable analyses, independent predictors of csPCa included smaller prostate volume (OR, 0.27; p < .001) and greater PSAD (OR, 3.09; p < .001). In multivariable models, bpMRI (compared with mpMRI) was not independently predictive of csPCa (p > .05). PSAD had an AUC for csPCa of 0.71 (95% CI, 0.56-0.87) in the bpMRI cohort versus 0.68 (95% CI, 0.42-0.93) in the mpMRI cohort. For detecting csPCa, a PSAD threshold of 0.15 ng/mL2 had NPV of 90% and PPV of 28%, in the bpMRI cohort versus NPV of 92% and PPV of 44% in the mpMRI cohort. CONCLUSION. The frequencies of csPCa were not significantly different at systematic biopsy performed after negative bpMRI and mpMRI examinations. PSAD had similar diagnostic utility for csPCa in the two cohorts. CLINICAL IMPACT. Either bpMRI or mpMRI, in combination with PSAD measurement, can help avoid negative prostate biopsies.
引用
- Gan, Kikano, Smith, et al. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI. AJR Am J Roentgenol. 2021. PMID: 34817189. doi:10.2214/AJR.21.26569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。